E-resources
Peer reviewed
Open access
-
Robinson, Ryan E; Mitsi, Elena; Nikolaou, Elissavet; Pojar, Sherin; Chen, Tao; Reiné, Jesús; Nyazika, Tinashe K; Court, James; Davies, Kelly; Farrar, Madlen; Gonzalez-Dias, Patricia; Hamilton, Josh; Hill, Helen; Hitchins, Lisa; Howard, Ashleigh; Hyder-Wright, Angela; Lesosky, Maia; Liatsikos, Konstantinos; Matope, Agnes; McLenaghan, Daniella; Myerscough, Christopher; Murphy, Annabel; Solórzano, Carla; Wang, Duolao; Burhan, Hassan; Gautam, Manish; Begier, Elizabeth; Theilacker, Christian; Beavon, Rohini; Anderson, Annaliesa S; Gessner, Bradford D; Gordon, Stephen B; Collins, Andrea M; Ferreira, Daniela M
American journal of respiratory and critical care medicine, 12/2022, Volume: 206, Issue: 11Journal Article
serotype 3 (SPN3) is a cause of invasive pneumococcal disease and associated with low carriage rates. Following the introduction of pediatric 13-valent pneumococcal conjugate vaccine (PCV13) programs, SPN3 declines are less than other vaccine serotypes and incidence has increased in some populations coincident with a shift in predominant circulating SPN3 clade, from I to II. A human challenge model provides an effective means for assessing the impact of PCV13 on SPN3 in the upper airway. To establish SPN3's ability to colonize the nasopharynx using different inoculum clades and doses, and the safety of an SPN3 challenge model. In a human challenge study involving three well-characterized and antibiotic-sensitive SPN3 isolates (PFESP306 clade Ia, PFESP231 no clade, and PFESP505 clade II), inoculum doses (10,000, 20,000, 80,000, and 160,000 cfu/100 μl) were escalated until maximal colonization rates were achieved, with concurrent acceptable safety. Presence and density of experimental SPN3 nasopharyngeal colonization in nasal wash samples, assessed using microbiological culture and molecular methods, on Days 2, 7, and 14 postinoculation. A total of 96 healthy participants (median age 21, interquartile range 19-25) were inoculated ( = 6-10 per dose group, 10 groups). Colonization rates ranged from 30.0-70.0% varying with dose and isolate. 30.0% (29/96) reported mild symptoms (82.8% 24/29 developed a sore throat); one developed otitis media requiring antibiotics. No serious adverse events occurred. An SPN3 human challenge model is feasible and safe with comparable carriage rates to an established Serotype 6B human challenge model. SPN3 carriage may cause mild upper respiratory symptoms.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.